Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review

Maryam Noori,Farideh Jafari-Raddani,Zeinab Davoodi-Moghaddam,Mahda Delshad,Saeid Safiri,Davood Bashash

DOI: https://doi.org/10.1186/s12935-023-03183-3

IF: 6.429

2024-01-05

Cancer Cell International

Abstract:Abstract In the Modern era, immune checkpoint inhibitors (ICIs) have been the cornerstone of success in the treatment of several malignancies. Despite remarkable therapeutic advances, complex matrix together with significant molecular and immunological differences have led to conflicting outcomes of ICI therapy in gastrointestinal (GI) cancers. As far we are aware, to date, there has been no study to confirm the robustness of existing data, and this study is the first umbrella review to provide a more comprehensive picture about ICIs’ efficacy and safety in GI malignancies. Systematic search on PubMed, Scopus, Web of Science, EMBASE, and Cochrane library identified 14 meta-analyses. The pooled analysis revealed that ICIs application, especially programmed death-1 (PD-1) inhibitors such as Camrelizumab and Sintilimab, could partially improve response rates in patients with GI cancers compared to conventional therapies. However, different GI cancer types did not experience the same efficacy; it seems that hepatocellular carcinoma (HCC) and esophageal cancer (EC) patients are likely better candidates for ICI therapy than GC and CRC patients. Furthermore, application of ICIs in a combined-modal strategy are perceived opportunity in GI cancers. We also assessed the correlation of PD-L1 expression as well as microsatellite status with the extent of the response to ICIs; overall, high expression of PD-L1 in GI cancers is associated with better response to ICIs, however, additional studies are required to precisely elaborate ICI responses with respect to microsatellite status in different GI tumors. Despite encouraging ICI efficacy in some GI cancers, a greater number of serious and fatal adverse events have been observed; further highlighting the fact that ICI therapy in GI cancers is not without cost, and further studies are required to utmost optimization of this approach in GI cancers.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in the treatment of gastrointestinal malignancies. Specifically, the research aims to answer the following key questions:

1. **How effective are ICIs in different types of gastrointestinal cancers?** The research explored the efficacy of ICIs in different gastrointestinal cancers such as hepatocellular carcinoma (HCC), gastric cancer (GC), esophageal cancer (EC) and colorectal cancer (CRC) by comprehensively analyzing the results of multiple systematic reviews and meta - analyses.

2. **Which types of gastrointestinal cancers are most likely to benefit from ICIs treatment?** The research found that HCC and EC patients seem to be more likely to benefit from ICIs treatment than GC and CRC patients.

3. **Which type of ICI performs the best?** Programmed death receptor - 1 (PD - 1) inhibitors such as Camrelizumab and Sintilimab were specifically mentioned. These drugs have shown the effect of improving the response rate in some gastrointestinal cancer patients.

4. **Do predictive biomarkers (such as PD - L1 expression and microsatellite status) help to select patients who are most likely to benefit from ICIs treatment?** The research indicates that high PD - L1 expression is associated with a better ICI response, but more research is needed to precisely clarify the role of microsatellite status in different gastrointestinal tumors.

5. **In terms of adverse events, how do ICIs compare with traditional therapies?** Although ICIs have shown encouraging efficacy in some gastrointestinal cancers, more severe and fatal adverse events have also been observed, which indicates that the application of ICIs treatment in gastrointestinal cancers is not without risks, and future research needs to further optimize this treatment method.

Through the exploration of these questions, the research aims to provide clinicians with a more comprehensive perspective in order to better guide the application of ICIs in the treatment of gastrointestinal cancers.